Research reveals first child after age 30 increases breast cancer risk by over 40%
HQ Team August 18, 2025: Research finds that women who have their first child after age 30 face a 40% to 45% higher.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team August 18, 2025: Research finds that women who have their first child after age 30 face a 40% to 45% higher.
HQ Team August 18, 2025: An implant called TAR-200 has shown remarkable results in treating high-risk bladder cancer. According to a recent Phase.
HQ Team August 16, 2025: Phase I clinical trial of the CD40 agonist antibody drug 2141-V11, developed by Rockefeller University’s Jeffrey V. Ravetch.
HQ Team August 14, 2025: The Annals of Internal Medicine has refused to retract a recent study that refuted any connection between aluminum.
August 14, 2025: A new study conducted by researchers at the University of Southampton in the UK and the Karolinska Institute in Sweden.
HQ Team August 13, 2025: Bayer and Kumquat Biosciences, a clinical-stage biotech, announced an exclusive global license and collaboration agreement worth $1.3 billion.
HQ Team August 12, 2025: Researchers from Jiangnan University in China have discovered a potential natural alternative to Ozempic, a popular GLP-1 receptor.
HQ Team August 12, 2025: A new study published in the journal Nature Medicine has shown promising results for an experimental vaccine, ELI-002.
HQ Team August 12, 2025: A study published in the journal Global Change Biology has revealed that lightning kills approximately 320 million trees.
HQ Team August 11, 2025: The US Food and Drug Administration (FDA) has granted approval to VIZZ (aceclidine ophthalmic solution 1.44%), an innovative.